The IPO Buzz: Clear Street (CLRS Proposed) in Focus in $2.4 Billion Week After Dow 50K

Clear Street Group (CLRS Proposed) is getting attention with its $1 billion IPO this week. The profitable New York-based FinTech company – a trading, clearing and risk-management platform – is a money machine. Clear Street Group is going public in the biggest deal on tap in the week after the Dow Jones Industrial Average closed above 50K for the first time on Friday, Feb. 6, 2026.

Coincidence or not: Clear Street Group’s stock is expected to start trading on the NASDAQ on Friday, Feb. 13 – the day before Valentine’s Day.

Clear Street’s IPO consists of 23.8 million shares at a price range of $40.00 to $44.00 to raise $1 billion – if priced at the $42.00 mid-point of its range.

Goldman Sachs, BofA Securities, Morgan Stanley, UBS Investment Bank and Clear Street are the lead joint book-runners.

Trio of Big Deals

This week’s compact IPO Calendar  includes three more large deals aiming to raise a total of $1.4 billion, listed below in order of pricing dates:

Pricing Tuesday night, Feb. 10, to trade Wednesday, Feb. 11, 2026

 – AGI (AGBK Proposed) is the second big Brazilian banking company to go public since late January. (PicS  N.V. (PICS) was the first.) AGI (AGBK Proposed)  caters to an older and mostly rural clientele through a combination of physical banking centers and online (FinTech) services. In contrast, PicS – with a younger and more affluent clientele – is focused on digital banking .– AGI’s IPO would raise $720 million – if priced at $16.50, the mid-point of its $15.00-to-$18.00 range, on 43.64 million shares.

Goldman Sachs, Morgan Stanley and Citigroup are the lead joint book-runners.

SOLV Energy (MWH Proposed), based in San Diego, is the second-largest solar power plant contractor in the U.S., based on 2024 revenues, and the seventh-largest contractor in power overall, according to Engineering News Record, an industry publication, as SOLV Energy noted in the prospectus. – The IPO would raise $481.8 million – if priced at the $23.50 mid-point of its $22.00-to-$25.00 range – on 20.5 million shares.

Jefferies and J.P. Morgan are the joint lead book-running managers.

Pricing Wednesday night, Feb. 11, to trade Thursday, Feb. 12, 2026:

ARKO Petroleum (APC Proposed), a carve-out by its parent, ARKO (ARKO), supplies fuel to customers in more than 30 states. Its business consists of three segments – (1) providing fuel to ARKO, one of the largest convenience store operators in the U.S.; (2) supplying fuel to third-party dealers under long-term contracts, and (3) selling fuel at its fleet fueling locations. – The IPO would raise $199.5 million – if priced at $19.00, the mid-point of its $18.00-to-$20.00 range – on 10.5 million shares.  

UBS Investment Bank, Raymond James, Stifel, Mizuho and Capital One Securities are the joint book-runners.

Small Uranium Deal Tonight

One small deal is also on this week’s IPO Calendar:

  • Jaguar Uranium (JAGU Proposed) – Canadian mining company with uranium exploration projects in Argentina and Colombia – 6 million shares at $4.00 to $6.00 to raise $30 million – The IPO is set to price tonight – Monday, Feb. 9, 2026, to trade Tuesday, Feb. 10, on the NYSE-American Exchange. Titan Partners Group is the sole book-runner.

Another deal – the NASDAQ uplisting/public offering of SharonAI Holdings  is described as an IPO by some. SharonAI Holdings’ public offering, however, is an uplisting to the NASDAQ from the OTC Market. Lucid Capital Markets is the sole book-runner.

Stay tuned.

(For more information about this company, please check the IPO Calendar and the individual IPO Profile found on the IPOScoop.com website.)

Note: Never trade on proposed symbols. They have been known to change and you might buy something on the OTC Bulletin Board.

To see what time the NASDAQ IPOs are expected to trade, please log in to: NASDAQTrader.com then scroll down to IPO Message.

Disclosure: Nobody on the IPOScoop.com staff has a position in any stocks mentioned above, nor do they trade or invest in IPOs. The IPOScoop.com staff does not issue advice, recommendations or opinions.